A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection
mBio · 2023
DOI: 10.1128/mbio.03482-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2023. Verfasst von Ashley M Rooney und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, Canada. Hauptthemen laut MEDLINE: Clostridioides difficile, Gastrointestinal Microbiome, Clostridium Infections, Microbiota. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Weston Foundation, Canadian Foundation for Innovation, University of Toronto Department of Medicine Integrating Challenge Grant.
Abstract (Originalsprache)
Intestinal colonization with pathogens and antimicrobial-resistant organisms (AROs) is associated with increased risk of infection. Fecal microbiota transplant (FMT) has successfully been used to cure recurrent Clostridioides difficile infection (rCDI) and to decolonize intestinal AROs. However, FMT has significant practical barriers to safe and broad implementation. Microbial consortia represent a novel strategy for ARO and pathogen decolonization, with practical and safety advantages over FMT. We undertook an investigator-initiated analysis of stool samples collected from previous interventional studies of a microbial consortium, microbial ecosystem therapeutic (MET-2), and FMT for rCDI before and after treatment. Our aim was to assess whether MET-2 was associated with decreased Pseudomonadota (Proteobacteria ) and antimicrobial resistance gene (ARG) burden with similar effects to FMT. Participants were selected for inclusion if baseline stool had Pseudomonadota relative abundance ≥10%. Pre- and post-treatment Pseudomonadota relative abundance, total ARGs, and obligate anaerobe and butyrate-producer relative abundances were determined by shotgun metagenomic sequencing. MET-2 administration had similar effects to FMT on microbiome outcomes. The median Pseudomonadota relative abundance decreased by four logs after MET-2 treatment, a greater decrease than that observed after FMT. Total ARGs decreased, while beneficial obligate anaerobe and butyrate-producer relative abundances increased. The observed microbiome response remained stable over 4 months post-administration for all outcomes. IMPORTANCE Overgrowth of intestinal pathogens and AROs is associated with increased risk of infection. With the rise in antimicrobial resistance, new therapeutic strategies that decrease pathogen and ARO colonization in the gut are needed. We evaluated whether a microbial consortium had similar effects to FMT on Pseudomonadota abundances and ARGs as well as obligate anaerobes and beneficial butyrate producers in individuals with high Pseudomonadota relative abundance at baseline. This study provides support for a randomized, controlled clinical trial of microbial consortia (such as MET-2) for ARO decolonization and anaerobe repletion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, Canada.
- Toronto General Hospital Research Institute, University Health Network , Toronto, Canada.
- NuBiyota, University of Guelph , Guelph, Canada.
- Department of Microbiology, Sinai Health , Toronto, Canada.
- Division of Infectious Diseases, University Health Network , Toronto, Canada.
- Infection Prevention and Control Department, University Health Network , Toronto, Canada.
ORCID-Profile: Ashley M Rooney, Emma Allen-Vercoe, Bryan Coburn
Förderung
- Weston Foundation
- Canadian Foundation for Innovation
- University of Toronto Department of Medicine Integrating Challenge Grant
Zitieren
APA
Rooney, A. M., Cochrane, K., Fedsin, S., Yao, S., Anwer, S., Dehmiwal, S., Hota, S., Poutanen, S., Allen-Vercoe, E., Coburn, B., & MTOP Investigators (2023). A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection. mBio. https://doi.org/10.1128/mbio.03482-22
Vancouver
Rooney AM, Cochrane K, Fedsin S, Yao S, Anwer S, Dehmiwal S, et al. A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection. mBio. 2023. doi:10.1128/mbio.03482-22
BibTeX
@article{Rooney2023,
author = {Rooney, Ashley M and Cochrane, Kyla and Fedsin, Stephanie and Yao, Samantha and Anwer, Shaista and Dehmiwal, Satyender and Hota, Susy and Poutanen, Susan and Allen-Vercoe, Emma and Coburn, Bryan and MTOP Investigators, MTOP Investigators},
title = {A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection},
journal = {mBio},
year = {2023},
doi = {10.1128/mbio.03482-22}
}
EUVIMED